ChemoCentryx Regains Crohn’s Candidate Vercirnon From GSK
This article was originally published in The Pink Sheet Daily
GSK will continue development of a rheumatoid arthritis candidate optioned from ChemoCentryx in 2011 and is expected to decide before year’s end on whether to license a Phase II candidate for renal vasculitis from the California biotech.
You may also be interested in...
SHIELD-1 failure puts the entire 2,500-patient plus Phase III clinical program in limbo as GSK rethinks its Crohn’s disease approach and partner ChemoCentryx’s stock loses close to half its value.
Lumenis’ surgical business includes the MOSES laser system for minimally invasive urology surgery which will complement Boston Scientific’s LithoVue ureteroscope.
Private Company Edition: Clover’s $230m financing was the largest of recent mega-rounds. Century Therapeutics ($160m), Vividion ($135m) and eGenesis ($125m) also raised big rounds and investors Foresite Capital ($969m), Sofinnova Partners ($540m) and OMX Ventures ($150m) raised new VC funds.